Non-haematological uses of cord blood stem cells

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Summary Embryonic stem (ES) cell therapies are often promoted as the optimal stem cell source for regenerative medicine applications because of their ability to develop into any tissue in the body. Unfortunately, ES cell applications are currently limited by ethical, political, biological and regulatory hurdles. However, multipotent non-ES cells are available in large numbers in umbilical cord blood (CB). CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopaedic, neurological and endocrine diseases. In addition, the recent use of CB in several regenerative medicine clinical studies has demonstrated its pluripotent nature. Here we review the latest developments in the use of CB in regenerative medicine. Examples of these usages include cerebral palsy and type I diabetes. The numbers of individuals affected with each of these diseases are estimated at 10 000 infants diagnosed with cerebral palsy annually and 15 000 youths diagnosed with type 1 diabetes annually. A summary of the initial results from such clinical studies using autologous cord blood stem cells will be presented.

Original languageEnglish (US)
Pages (from-to)177-184
Number of pages8
JournalBritish Journal of Haematology
Volume147
Issue number2
DOIs
StatePublished - Oct 2009

Fingerprint

Fetal Blood
Blood Cells
Stem Cells
Regenerative Medicine
Cerebral Palsy
Embryonic Stem Cells
Type 1 Diabetes Mellitus
Endocrine System Diseases
Eye Diseases
Cell- and Tissue-Based Therapy
Endothelium
Orthopedics
Cardiovascular Diseases

Keywords

  • Regenerative medicine
  • Stem cells
  • Tissue engineering
  • Umbilical cord blood

ASJC Scopus subject areas

  • Hematology

Cite this

Non-haematological uses of cord blood stem cells. / Harris, David T.

In: British Journal of Haematology, Vol. 147, No. 2, 10.2009, p. 177-184.

Research output: Contribution to journalArticle

@article{4abbd1bce2514970ac3e3bca70d29302,
title = "Non-haematological uses of cord blood stem cells",
abstract = "Summary Embryonic stem (ES) cell therapies are often promoted as the optimal stem cell source for regenerative medicine applications because of their ability to develop into any tissue in the body. Unfortunately, ES cell applications are currently limited by ethical, political, biological and regulatory hurdles. However, multipotent non-ES cells are available in large numbers in umbilical cord blood (CB). CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopaedic, neurological and endocrine diseases. In addition, the recent use of CB in several regenerative medicine clinical studies has demonstrated its pluripotent nature. Here we review the latest developments in the use of CB in regenerative medicine. Examples of these usages include cerebral palsy and type I diabetes. The numbers of individuals affected with each of these diseases are estimated at 10 000 infants diagnosed with cerebral palsy annually and 15 000 youths diagnosed with type 1 diabetes annually. A summary of the initial results from such clinical studies using autologous cord blood stem cells will be presented.",
keywords = "Regenerative medicine, Stem cells, Tissue engineering, Umbilical cord blood",
author = "Harris, {David T.}",
year = "2009",
month = "10",
doi = "10.1111/j.1365-2141.2009.07767.x",
language = "English (US)",
volume = "147",
pages = "177--184",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Non-haematological uses of cord blood stem cells

AU - Harris, David T.

PY - 2009/10

Y1 - 2009/10

N2 - Summary Embryonic stem (ES) cell therapies are often promoted as the optimal stem cell source for regenerative medicine applications because of their ability to develop into any tissue in the body. Unfortunately, ES cell applications are currently limited by ethical, political, biological and regulatory hurdles. However, multipotent non-ES cells are available in large numbers in umbilical cord blood (CB). CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopaedic, neurological and endocrine diseases. In addition, the recent use of CB in several regenerative medicine clinical studies has demonstrated its pluripotent nature. Here we review the latest developments in the use of CB in regenerative medicine. Examples of these usages include cerebral palsy and type I diabetes. The numbers of individuals affected with each of these diseases are estimated at 10 000 infants diagnosed with cerebral palsy annually and 15 000 youths diagnosed with type 1 diabetes annually. A summary of the initial results from such clinical studies using autologous cord blood stem cells will be presented.

AB - Summary Embryonic stem (ES) cell therapies are often promoted as the optimal stem cell source for regenerative medicine applications because of their ability to develop into any tissue in the body. Unfortunately, ES cell applications are currently limited by ethical, political, biological and regulatory hurdles. However, multipotent non-ES cells are available in large numbers in umbilical cord blood (CB). CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopaedic, neurological and endocrine diseases. In addition, the recent use of CB in several regenerative medicine clinical studies has demonstrated its pluripotent nature. Here we review the latest developments in the use of CB in regenerative medicine. Examples of these usages include cerebral palsy and type I diabetes. The numbers of individuals affected with each of these diseases are estimated at 10 000 infants diagnosed with cerebral palsy annually and 15 000 youths diagnosed with type 1 diabetes annually. A summary of the initial results from such clinical studies using autologous cord blood stem cells will be presented.

KW - Regenerative medicine

KW - Stem cells

KW - Tissue engineering

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=70349687214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349687214&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07767.x

DO - 10.1111/j.1365-2141.2009.07767.x

M3 - Article

VL - 147

SP - 177

EP - 184

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -